Melatonin protects against myocardial doxorubicin toxicity in rats: Role of physiological concentrations

Journal of Pineal Research

Volumn 35, Issue 4, 2003, Pages 257-261

  Sahna, Engin ^a   Parlakpinar, Hakan ^b   Ozer, Mehmet K ^b   Ozturk, Feral ^b   Ozugurlu, Fikret ^b   Acet, Ahmet ^b  

^a FIRAT UNIVERSITY   (Turkey)

^b INONU UNIVERSITY   (Turkey)

Author keywords

Doxorubicin; Heart; Melatonin; Pinealectomy; Rats

Indexed keywords

DOXORUBICIN; MALONALDEHYDE; MELATONIN; MEMBRANE LIPID; OXYGEN RADICAL; SCAVENGER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOTOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HEART PROTECTION; LIPID PEROXIDATION; MICROSCOPY; NONHUMAN; PINEALECTOMY; RAT;

ANIMALS; ANTIOXIDANTS; DOXORUBICIN; HEART; MALONDIALDEHYDE; MELATONIN; MYOCARDIUM; PINEAL GLAND; RATS;

EID: 0242333263     PISSN: 07423098     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-079X.2003.00084.x     Document Type: Article

References (34)

1. BOOSER DJ, HORTOBAGYI GN. Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs 1994; 47:223-258.
2. MORISHIMA I, MATSUI H, MUKAWA H et al. Melatonin, a pineal hormone with antioxidant property, protects against adriamycin cardiomyopathy in rats. Life Sci 1998; 63:511-521.
3. KITAKAZE M. Doxorubicin, to treat cancers or to cause cardiac injury, that is the question. Cardiovasc Drugs Ther 2001; 15:199-200.
4. XU MF, TANG PL, QIAN ZM et al. Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci 2001; 68:889-901.
5. LI T, DANELISEN I, SINGAL PK. Early changes in myocardial antioxidant enzymes in rats treated with adriamycin. Mol Cell Biochem 2002; 232:19-26.
6. SINGAL PK, SIVESKI-ILISKOVIC N, HILL M et al. Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. J Mol Cell Cardiol 1995; 27:1055-1063.
7. GARCIA JJ, REITER RJ, GUERRERO JM et al. Melatonin prevents changes in microsomal membrane fluidity during induced lipid peroxidation. FEBS Lett 1997; 408:297-300.
8. REITER RJ, GUERRERO JM, GARCIA JJ et al. Reactive oxygen intermediates, molecular damage, and aging. Relation to melatonin. Ann N Y Acad Sci 1998; 854:410-424.
9. REITER RJ, TAN DX, MANCHESTER LC et al. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a review of the evidence. Cell Biochem Biophys 2001; 34:237-256.
10. KARBOWNIK M, REITER RJ. Melatonin protects against oxidative stress caused by delta-aminolevulinic acid: implications for cancer reduction. Cancer Invest 2002; 20:276-286.
11. LIU X, CHEN Z, CHUA CC et al. Melatonin as an effective protector against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 2002; 283:254-263.
12. AGAPITO MT, ANTOLIN Y, DEL BRIO MT et al. Protective effect of melatonin against adriamycin toxicity in the rat. J Pineal Res 2001; 31:23-30.
13. REITER RJ, TAN DX, SAINZ RM et al. Melatonin protects the heart against both ischemia/reperfusion injury and chemotherapeutic drugs. Cardiovasc Drugs Ther 2002; 16:5-6.
14. SAHNA E, OLMEZ E, ACET A. Effects of physiological and pharmacological concentrations of melatonin on ischemia-reperfusion arrhythmias in rats: can the incidence of sudden cardiac death be reduced? J Pineal Res 2002; 32:194-198.
15. SAHNA E, ACET A, OZER MK et al. Myocardial ischemia-reperfusion in rats: reduction of infarct size by either supplemental physiological or pharmacological doses of melatonin. J Pineal Res 2002; 30:234-238.
16. HOFFMAN RA, REITER RJ. Rapid pinealectomy in hamsters and other small rodents. Anat Rec 1965; 153:19-21.
17. VERMEULEN NPE, BALDEW GS. The role of lipid peroxidation in the nephrotoxicity of cisplatin. Biochem Pharmacol 1992; 44:1193.
18. REITER RJ, TAN DX, SAINZ RM et al. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 2002; 54:1299-1321.
19. REITER RJ, CRAFT CM, JOHNSON JE Jr et al. Age-associated reduction in nocturnal pineal melatonin levels in female rats. Endocrinology 1981; 109:1295-1297.
20. GRACE MS, CAHILL GM, BESHARSE JC. Melatonin deacetylation: retinal vertebrate class distribution and Xenopus laevis tissue distribution. Brain Res 1991; 559:56-63.
21. REITER RJ, TAN D, KIM SJ et al. Augmentation of indices of oxidative damage in life-long melatonin-deficient rats. Mech Ageing Dev 1999; 110:157-173.
22. ALLEGRA M, REITER RJ, TAN DX et al. The chemistry of melatonin's interaction with reactive species. J Pineal Res 2003; 34:1-10.
23. GITTO E, TAN DX, REITER RJ et al. Individual and synergistic antioxidative actions of melatonin: studies with vitamin E, vitamin C, glutathione and desferrioxamine (desferoxamine) in rat liver homogenates. J Pharm Pharmacol 2003; 53:1393-1401.
24. REITER RJ, TAN DX, OSUNA C et al. Actions of melatonin in the reduction of oxidative stress. A review. J Biomed Sci 2000; 7:444-458.
25. MARTIN V, SAINZ RM, ANTOLIN I et al. Several antioxidant pathways are involved in astrocyte protection by melatonin. J Pineal Res 2002; 33:204-212.
26. TAN DX, MANCHESTER LC, REITER RJ et al. Significance of melatonin in antioxidative defense system: reactions and products. Biol Signals Recept 2000; 9:137-159.
27. CUZZOCREA S, REITER RJ. Pharmacological action of melatonin in shock, inflammation and ischemia/reperfusion injury. Eur J Pharmacol 2001; 426:1-10.
28. WAHAB MHA, AKOUL EEMS, ABDEL-AZIZ AH. Modulatory effects of melatonin and vitamin E on doxorubicin-induced cardiotoxicity in Ehrlich ascites carcinoma-bearing mice. Tumori 2000; 86:157-162.
29. GRANZOTTO M, RAPOZZI V, DECORTI G et al. Effects of melatonin on doxorubicin cytotoxicity in sensitive and pleiotropically resistant tumor cells. J Pineal Res 2001; 31: 206-213.
30. PETRANKA J, BALDWIN W, BIERMANN J et al. The oncostatic action of melatonin in an ovarian carcinoma cell line. J Pineal Res 1999; 26:129-136.
31. TAMARKIN L, COHEN M, ROSELLE D et al. Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat. Cancer Res 1981; 41:4432-4436.
32. REITER RJ, TAN DX, QI W et al. Pharmacology and physiology of melatonin in the reduction of oxidative stress in vivo. Biol Signals Recept 2000; 9:160-171.
33. BENOT S, GOBERNA R, REITER RJ et al. Physiological levels of melatonin contribute to the antioxidant capacity of human serum. J Pineal Res 1999; 27:59-64.
34. MENENDEZ-PELAEZ A, REITER RJ. Distribution of melatonin in mammalian tissues: the relative importance of nuclear versus cytosolic localization. J Pineal Res 1993; 1:59-69.